MAP Pharmaceuticals Raises $50M
Mountain View-based MAP Pharmaceuticals has riased $50M in its Series D round, the company said today. MAP is developing treatments for respiratory and CNS diseases. Investors in the firm were D.E. Shaw group, and previous investors Perseus-Soros Biopharmaceutical Fund, Pequot Ventures, Brookside Capital, Bay City Capital, and Skyline Ventures.
posted on Wednesday, March 28, 2007 (Link to more information)
Related companies:
Map My Customers, Inc.
Related stories:
> Bridge Pharmaceuticals Raises $35M
> MicuRx Raises $10M
> Third Rock Ventures Raises $426M Fund, Sets Up Shop In San Francisco
> TransOral Pharmaceuticals Raises $40M
> Anthera Pharmaceuticals Raises $36M
silicontap.com Home